Breast cancer: correlation of receptor status with clinical presentation, stage of disease, histopathological grade and short term outcome
DOI:
https://doi.org/10.18203/2349-2902.isj20191270Keywords:
Breast cancer, Receptor status, Triple negative breast cancer, Nottingham grade, Locally advanced breast cancerAbstract
Background: Breast cancer is the commonest female cancer representing a quarter of all cancers worldwide. An important development in breast cancer management was the realization of role of hormone receptors in disease. Thus, the present study was carried out to evaluate the receptor status and its correlation with clinical presentation, stage, grade and short term outcome.
Methods: All female patients with lump in breast confirmed as breast cancer were included and their receptor status was evaluated using immunohistochemistry.
Results: A total of 147 patients with a mean age of 50.16±12.08 years were enrolled. Almost half of the patients (48.3%) of the patients were found to have locally advanced breast cancer. Of the 147 patients, 91.49% tumours were either Nottingham grade 2 or 3. Triple negative breast cancer (TNBC) was the commonest subtype seen in 43.54% patients. On correlating the results with receptor status, it was found that TNBC patients were younger than HER2neu positive and ER PR positive patients. Also, TNBC patients had a longer duration of lump and the lump was of larger size at presentation. On correlating receptor status with tumour biology it was seen that more than half (54.69%) of the patients who were triple negative had a grade 3 tumour and poorer disease free survival and overall survival.
Conclusions: In conclusion it is seen that TNBC forms a majority of the cases in the central Indian population with more aggressive presentations and outcomes. Absence of any targeted therapies against them leads to a worse DFS and overall survival.
Metrics
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5):359-86.
Gupta A, Shridhar K, Dhillon PK. A review of breast cancer awareness among women in India: Cancer literate or awareness deficit? Eur J Cancer. 2015;51(14):2058-66.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
Hawkins RA, Roberts MM, Forrest AP. Oestrogen receptors and breast cancer: current status. British J Surg. 1980;67(3):153-69.
Mori I, Yang Q, Kakudo K. Predictive and prognostic markers for invasive breast cancer. Pathology Int. 2002;52(3):186-94.
Ammaji DS, Suvarchala DA, Yogesh D. To study the clinical and pathological staging of breast cancer and to correlate these findings with status of the tumor markers. Paripex-Indian J Res. 2018;6(4):13-6.
Hathila TN, Sangle RB, Doshi SA, Firdaus DA, Rupani MP. A prospectivestudy of estrogen, progestrone and HER2neu receptor in cases of breast cancer in a tertiary care hospital of Bhavnagar, Gujarat, Western India. National J Med Res. 2015;5(3):185-9.
Takalkar UV, Asegaonkar SB, Kulkarni U, Kodlikeri PR, Kulkarni U, Saraf M, et al. Clinicopathological profile of breast cancer patients at a tertiary care hospital in marathwada region of Westen India. Asian Pac J Cancer Prev. 2016;17(4):2195-8.
Balasubramaniam S, Rotti S, Vivekanandam S. Risk factors of female breast carcinoma: a case control study at Puducherry. Indian J Cancer. 2013;50(1):65.
Akhtar M, Akulwar V, Gandhi D, Chandak K. Is locally advanced breast cancer a neglected disease? Indian J Cancer. 2011;48(4):403.
Singh R, Gupta S, Pawar SB, Pawar RS, Gandham SV, Prabhudesai S. Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India. Journal Cancer Res Therap. 2014;10(1):26.
Sofi GN, Sofi JN, Nadeem R, Shiekh RY, Khan FA, Sofi AA, et al. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pacific J Cancer Prev. 2012;13(10):5047-52.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical Med Res. 2009;7(1-2):4-13.
Downloads
Published
How to Cite
Issue
Section
